FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210835488> ?p ?o ?g. }

• W4210835488 abstract "Abstract Funding Acknowledgements Type of funding sources: None. Background Cardiovascular complications of cancer therapy are increasingly becoming a significant medical issue. Hence, the role of cardiovascular imaging in the assessment of baseline cardiovascular risk is becoming increasingly important. Current guidelines recommend a baseline transthoracic echocardiogram (TTE) prior to commencement of cardiotoxic chemotherapy (CC) but the uptake is presently inconsistent. Purpose Our study aimed to determine the uptake of a baseline TTE in a cohort of patients with solid organ malignancies (SOM) prior to commencing their treatment and to examine the patterns of uptake based on the risk of development of cardiotoxicity. Methods Patients with a SOM admitted to our institution between 2014-18 were examined. Demographic data, clinical comorbidities, cancer type, and chemotherapeutic regimens used were obtained from the patient’s electronic medical record. Included patients were divided into those receiving one of the 8 CC classes identified in the Cardio-Oncology Study Group and International Cardio-Oncology Society (COSG/ICOS) 2020 position statement1, and those who did not (control group). Those receiving CC were further stratified into risk groups according to the proformas proposed by the COSG/ICOS, while patients receiving immunotherapy for whom a proforma was not available, were considered a separate group. The uptake patterns of TTE in each group determined. Results Of 800 patients reviewed, 712 patients were included, and categorised into groups as shown in figure 1. Patients treated with CC had low uptake of a baseline TTE, and there was no difference compared to controls (14.4% vs 13.9%, p = 0.9). They were however more likely to have received a TTE during the course of treatment (32.3% vs 23.2%, p = 0.009). Figure 2 shows the rates of baseline TTE stratified by risk group. Compared to patients not on CC, only very high risk patients had a higher rate of baseline TTE (p &lt; 0.001), while low risk patients had lower rates (p = 0.005). Compared to those not on CC, there was no difference in the rate of baseline TTE amongst immunotherapy patients, medium risk and high risk patients. Conclusion The uptake of baseline TTE in accordance with guidelines amongst patients receiving CC was very low. Based on the risk stratification proformas proposed by the COSG/ICOS, only very high risk patients were having a baseline TTE more frequently than those not treated with CC. The risk of future cardiotoxicity amongst low, medium and high risk patients, and those receiving immunotherapy, appears to be underappreciated, as these patients were not screened by TTE prior to commencing therapy. Increasing awareness of the agents that cause cardiotoxicity, and the establishment of formal protocols for these patients, may increase compliance with recommendations for TTE prior to commencing CC. Abstract Figure. Distribution of patients by risk group Abstract Figure. Percentage of patients with baseline TTE" @default.
• W4210835488 created "2022-02-09" @default.
• W4210835488 creator A5001568969 @default.
• W4210835488 creator A5024473465 @default.
• W4210835488 creator A5032295757 @default.
• W4210835488 creator A5045858895 @default.
• W4210835488 creator A5046787496 @default.
• W4210835488 creator A5075364446 @default.
• W4210835488 date "2022-02-01" @default.
• W4210835488 modified "2023-09-27" @default.
• W4210835488 title "Uptake of echocardiography amongst different risk groups for patients treated with cardiotoxic chemotherapy" @default.
• W4210835488 doi "https://doi.org/10.1093/ehjci/jeab289.310" @default.
• W4210835488 hasPublicationYear "2022" @default.
• W4210835488 type Work @default.
• W4210835488 citedByCount "0" @default.
• W4210835488 crossrefType "journal-article" @default.
• W4210835488 hasAuthorship W4210835488A5001568969 @default.
• W4210835488 hasAuthorship W4210835488A5024473465 @default.
• W4210835488 hasAuthorship W4210835488A5032295757 @default.
• W4210835488 hasAuthorship W4210835488A5045858895 @default.
• W4210835488 hasAuthorship W4210835488A5046787496 @default.
• W4210835488 hasAuthorship W4210835488A5075364446 @default.
• W4210835488 hasBestOaLocation W42108354881 @default.
• W4210835488 hasConcept C121608353 @default.
• W4210835488 hasConcept C126322002 @default.
• W4210835488 hasConcept C143998085 @default.
• W4210835488 hasConcept C2776694085 @default.
• W4210835488 hasConcept C2778233292 @default.
• W4210835488 hasConcept C71924100 @default.
• W4210835488 hasConcept C72563966 @default.
• W4210835488 hasConceptScore W4210835488C121608353 @default.
• W4210835488 hasConceptScore W4210835488C126322002 @default.
• W4210835488 hasConceptScore W4210835488C143998085 @default.
• W4210835488 hasConceptScore W4210835488C2776694085 @default.
• W4210835488 hasConceptScore W4210835488C2778233292 @default.
• W4210835488 hasConceptScore W4210835488C71924100 @default.
• W4210835488 hasConceptScore W4210835488C72563966 @default.
• W4210835488 hasIssue "Supplement_1" @default.
• W4210835488 hasLocation W42108354881 @default.
• W4210835488 hasOpenAccess W4210835488 @default.
• W4210835488 hasPrimaryLocation W42108354881 @default.
• W4210835488 hasRelatedWork W115008929 @default.
• W4210835488 hasRelatedWork W2029518877 @default.
• W4210835488 hasRelatedWork W2086253356 @default.
• W4210835488 hasRelatedWork W2315085516 @default.
• W4210835488 hasRelatedWork W2371666691 @default.
• W4210835488 hasRelatedWork W2378355431 @default.
• W4210835488 hasRelatedWork W2603773853 @default.
• W4210835488 hasRelatedWork W2928209699 @default.
• W4210835488 hasRelatedWork W2998970160 @default.
• W4210835488 hasRelatedWork W4283764677 @default.
• W4210835488 hasVolume "23" @default.
• W4210835488 isParatext "false" @default.
• W4210835488 isRetracted "false" @default.
• W4210835488 workType "article" @default.